miR-485-5p binding site SNP rs8752 in HPGD gene is associated with breast cancer risk

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  He, Na ^a   Zheng, Hong ^a   Li, Pei ^a   Zhao, Yanrui ^a   Zhang, Wei ^b   Song, Fengju ^a   Chen, Kexin ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROXYPROSTAGLANDIN DEHYDROGENASE; ESTROGEN RECEPTOR; MICRORNA; MICRORNA 485 5P; UNCLASSIFIED DRUG; 15-HYDROXYPROSTAGLANDIN DEHYDROGENASE; 3' UNTRANSLATED REGION; MIRN485 MICRORNA, HUMAN;

3' UNTRANSLATED REGION; ADULT; ARTICLE; BINDING SITE; BREAST CANCER; CANCER RISK; CANCER STAGING; CASE CONTROL STUDY; CHINESE; CONTROLLED STUDY; FEMALE; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENOTYPE; HPGD GENE; HUMAN; MAJOR CLINICAL STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; BREAST TUMOR; GENE EXPRESSION REGULATION; GENE FREQUENCY; GENETIC PREDISPOSITION; GENETICS; METABOLISM; MIDDLE AGED; RISK FACTOR; RNA INTERFERENCE;

3' UNTRANSLATED REGIONS; BINDING SITES; BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYDROXYPROSTAGLANDIN DEHYDROGENASES; MICRORNAS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; RNA INTERFERENCE;

EID: 84903903673     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0102093     Document Type: Article

References (45)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
2. Babashah S, Soleimani M (2011) The oncogenic and tumour suppressive roles of microRNAs in cancer and apoptosis. Eur J Cancer 47: 1127-1137.
3. Fowler A, Thomson D, Giles K, Maleki S, Mreich E, et al. (2011) miR-124a is frequently down-regulated in glioblastoma and is involved in migration and invasion. Eur J Cancer 47: 953-963.
4. Yan LX, Huang XF, Shao Q, Huang MY, Deng L, et al. (2008) MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA 14: 2348-2360.
5. Yu Z, Wang C, Wang M, Li Z, Casimiro MC, et al. (2008) A cyclin D1/microRNA 17/20 regulatory feedback loop in control of breast cancer cell proliferation. J Cell Biol 182: 509-517.
6. Wu H, Zhu S, Mo YY (2009) Suppression of cell growth and invasion by miR-205 in breast cancer. Cell Res 19: 439-448.
7. Winter J, Diederichs S (2011) MicroRNA biogenesis and cancer. Methods Mol Biol 676: 3-22.
8. Chen K, Song F, Calin GA, Wei Q, Hao X, et al. (2008) Polymorphisms in microRNA targets: a gold mine for molecular epidemiology. Carcinogenesis 29: 1306-1311.
9. Landi D, Gemignani F, Naccarati A, Pardini B, Vodicka P, et al. (2008) Polymorphisms within micro-RNA-binding sites and risk of sporadic colorectal cancer. Carcinogenesis 29: 579-584.
10. Saetrom P, Biesinger J, Li SM, Smith D, Thomas LF, et al. (2009) A risk variant in an miR-125b binding site in BMPR1B is associated with breast cancer pathogenesis. Cancer Res 69: 7459-7465.
11. Chin LJ, Ratner E, Leng S, Zhai R, Nallur S, et al. (2008) A SNP in a let-7 microRNA complementary site in the KRAS 3′ untranslated region increases non-small cell lung cancer risk. Cancer Res 68: 8535-8540.
12. Hiard S, Charlier C, Coppieters W, Georges M, Baurain D (2010) Patrocles: a database of polymorphic miRNA-mediated gene regulation in vertebrates. Nucleic Acids Res 38: D640-D651.
13. Bhattacharya A, Ziebarth JD, Cui Y (2014) PolymiRTS Database 3.0: linking polymorphisms in microRNAs and their target sites with human diseases and biological pathways. Nucleic Acids Res 42: D86-D91.
14. Yu Z, Li Z, Jolicoeur N, Zhang L, Fortin Y, et al. (2007) Aberrant allele frequencies of the SNPs located in microRNA target sites are potentially associated with human cancers. Nucleic Acids Res 35: 4535-4541.
15. Saunders MA, Liang H, Li WH (2007) Human polymorphism at microRNAs and microRNA target sites. Proc Natl Acad Sci U S A 104: 3300-3305.
16. Landi D, Gemignani F, Barale R, Landi S (2008) A catalog of polymorphisms falling in microRNA-binding regions of cancer genes. DNA Cell Biol 27: 35-43.
17. Zhang L, Liu Y, Song F, Zheng H, Hu L, et al. (2011) Functional SNP in the microRNA-367 binding site in the 3'UTR of the calcium channel ryanodine receptor gene 3 (RYR3) affects breast cancer risk and calcification. Proc Natl Acad Sci U S A 108: 13653-13658.
18. Song F, Zheng H, Liu B, Wei S, Dai H, et al. (2009) An miR-502-binding site single-nucleotide polymorphism in the 3'-untranslated region of the SET8 gene is associated with early age of breast cancer onset. Clin Cancer Res 15: 6292-6300.
19. Chen J, Qin Z, Jiang Y, Wang Y, He Y, et al. (2014) Genetic Variations in the Flanking Regions of miR-101-2 Are Associated with Increased Risk of Breast Cancer. PLoS One 9: e86319.
20. Gilam A, Edry L, Mamluk-Morag E, Bar-Ilan D, Avivi C, et al. (2013) Involvement of IGF-1R regulation by miR-515-5p modifies breast cancer risk among BRCA1 carriers. Breast Cancer Res Treat 138: 753-760.
21. Jedlinski DJ, Gabrovska PN, Weinstein SR, Smith RA, Griffiths LR (2011) Single nucleotide polymorphism in hsa-mir-196a-2 and breast cancer risk: a case control study. Twin Res Hum Genet 14: 417-421.
22. Nicoloso MS, Sun H, Spizzo R, Kim H, Wickramasinghe P, et al. (2010) Single-nucleotide polymorphisms inside microRNA target sites influence tumor susceptibility. Cancer Res 70: 2789-2798.
23. Wang L, Liu W, Jiang W, Lin J, Jiang Y, et al. (2012) A miRNA binding site single-nucleotide polymorphism in the 3′-UTR region of the IL23R gene is associated with breast cancer. PLoS One 7: e49823.
24. Teo MT, Landi D, Taylor CF, Elliott F, Vaslin L, et al. (2012) The role of microRNA-binding site polymorphisms in DNA repair genes as risk factors for bladder cancer and breast cancer and their impact on radiotherapy outcomes. Carcinogenesis 33: 581-586.
25. Zheng H, Song F, Zhang L, Yang D, Ji P, et al. (2011) Genetic variants at the miR-124 binding site on the cytoskeleton-organizing IQGAP1 gene confer differential predisposition to breast cancer. Int J Oncol 38: 1153-1161.
26. Kontorovich T, Levy A, Korostishevsky M, Nir U, Friedman E (2010) Single nucleotide polymorphisms in miRNA binding sites and miRNA genes as breast/ovarian cancer risk modifiers in Jewish high-risk women. Int J Cancer 127: 589-597.
27. Saetrom P, Biesinger J, Li SM, Smith D, Thomas LF, et al. (2009) A risk variant in an miR-125b binding site in BMPR1B is associated with breast cancer pathogenesis. Cancer Res 69: 7459-7465.
28. Brendle A, Lei H, Brandt A, Johansson R, Enquist K, et al. (2008) Polymorphisms in predicted microRNA-binding sites in integrin genes and breast cancer: ITGB4 as prognostic marker. Carcinogenesis 29: 1394-1399.
29. Kang HS, Ahn SH, Mishra SK, Hong KM, Lee ES, et al. (2014) Association of polymorphisms and haplotypes in the insulin-like growth factor 1 receptor (IGF1R) gene with the risk of breast cancer in Korean women. PLoS One 9: e84532.
30. Jauliac S, Lopez-Rodriguez C, Shaw LM, Brown LF, Rao A, et al. (2002) The role of NFAT transcription factors in integrin-mediated carcinoma invasion. Nat Cell Biol 4: 540-544.
31. Li XQ, Li L, Xiao CH, Feng YM (2012) NEFL mRNA expression level is a prognostic factor for early-stage breast cancer patients. PLoS One 7: e31146.
32. Kang S, Kim B, Park SB, Jeong G, Kang HS, et al. (2013) Stage-specific methylome screen identifies that NEFL is downregulated by promoter hypermethylation in breast cancer. Int J Oncol 43: 1659-1665.
33. Chen Z, Xu L, Ye X, Shen S, Li Z, et al. (2013) Polymorphisms of microRNA sequences or binding sites and lung cancer: a meta-analysis and systematic review. PLoS One 8: e61008.
34. Lin M, Gu J, Eng C, Ellis LM, Hildebrandt MA, et al. (2012) Genetic polymorphisms in MicroRNA-related genes as predictors of clinical outcomes in colorectal adenocarcinoma patients. Clin Cancer Res 18: 3982-3991.
35. Slaby O, Bienertova-Vasku J, Svoboda M, Vyzula R (2012) Genetic polymorphisms and microRNAs: new direction in molecular epidemiology of solid cancer. J Cell Mol Med 16: 8-21.
36. Yang H, Dinney CP, Ye Y, Zhu Y, Grossman HB, et al. (2008) Evaluation of genetic variants in microRNA-related genes and risk of bladder cancer. Cancer Res 68: 2530-2537.
37. Lin J, Horikawa Y, Tamboli P, Clague J, Wood CG, et al. (2010) Genetic variations in microRNA-related genes are associated with survival and recurrence in patients with renal cell carcinoma. Carcinogenesis 31: 1805-1812.
38. Ryu YM, Myung SJ, Park YS, Yang DH, Song HJ, et al. (2013) Inhibition of 15-hydroxyprostaglandin dehydrogenase by Helicobacter pylori in human gastric carcinogenesis. Cancer Prev Res (Phila) 6: 349-359.
39. Wolf I, O'Kelly J, Rubinek T, Tong M, Nguyen A, et al. (2006) 15-hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer. Cancer Res 66: 7818-7823.
40. Ding Y, Tong M, Liu S, Moscow JA, Tai HH (2005) NAD+-linked 15-hydroxyprostaglandin dehydrogenase (15-PGDH) behaves as a tumor suppressor in lung cancer. Carcinogenesis 26: 65-72.
41. Backlund MG, Mann JR, Holla VR, Buchanan FG, Tai HH, et al. (2005) 15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer. J Biol Chem 280: 3217-3223.
42. Tong M, Tai HH (2004) Synergistic induction of the nicotinamide adenine dinucleotide-linked 15-hydroxyprostaglandin dehydrogenase by an androgen and interleukin-6 or forskolin in human prostate cancer cells. Endocrinology 145: 2141-2147.
43. Huang G, Eisenberg R, Yan M, Monti S, Lawrence E, et al. (2008) 15-Hydroxyprostaglandin dehydrogenase is a target of hepatocyte nuclear factor 3beta and a tumor suppressor in lung cancer. Cancer Res 68: 5040-5048.
44. Pham H, Eibl G, Vincenti R, Chong B, Tai HH, et al. (2008) 15-Hydroxyprostaglandin dehydrogenase suppresses K-RasV12-dependent tumor formation in Nu/Nu mice. Mol Carcinog 47: 466-477.
45. Li M, Xie J, Cheng L, Chang B, Wang Y, et al. (2008) Suppression of invasive properties of colorectal carcinoma SW480 cells by 15- hydroxyprostaglandin dehydrogenase gene. Cancer Invest 26: 905-912.